Current available therapies and future directions in the treatment of malignant gliomas

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 15-25

  Desjardins, Annick ^a   Reardon, David A ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Glioma; Kinase inhibitor; Targeted therapy

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 O BENZYLGUANINE; AFLIBERCEPT; AZD 1839; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CILENGITIDE; DEFOROLIMUS; DEXAMETHASONE; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; LONAFARNIB; PACLITAXEL; PERIFOSINE; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ANEMIA; AORTA THROMBOSIS; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN EDEMA; BRAIN HEMORRHAGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONVULSION; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; EVENING DOSAGE; FATIGUE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMONIA; PROTEINURIA; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 65349157703     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Cancer Facts and Figures 2005. Surveillance Research. American Cancer Society Inc. Atlanta, USA. 2005;1-60.
2. Statistical Report: Primary Brain Tumors in the United States, 1997-2001. Central Brain Tumor Registry of the United States. Hinsdale, USA. 2004.
3. Kleihues P, Cavenee WK. Pathology and genetics: Tumors of the nervous system. In: World Health Classification of tumors. International Agency for Research on Cancer, Albany, USA. 2000;314.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114(2):97-109.
5. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40(1):51-55.
6. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578.
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359(9311):1011-1018.
8. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
9. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296-307.
10. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
11. Friedman HS. Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? Clin Cancer Res. 2000;6(8):2967-2968.
12. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23(28):7178-7187.
13. Kleihues P, Cavenee WK. Pathology and Genetics Tumours of the Nervous System. IARC Press, Lyon, 2000;314.
14. Reijneveld JC, Voest EE, Taphoorn MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol. 2000;247:597-608.
15. Chaudhry LH, O'Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001;39:409-415.
16. Ke LD, Shi YX, Im SA, Chen X, Yung WK. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity I human glioma cell lines. Clin Cancer Res. 2000;6:2562-2572.
17. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
18. Samoto K, Ikezaki K. Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascualarization in human brain tumors. Cancer Res. 1995;55:1189-1193.
19. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis. 2002;5:237-256.
20. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
21. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
22. Ferrara N, Hillan KJ, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discov. 2004;3:391-400.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004;350:2335-2342.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-2550.
25. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
26. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
27. Vredenburgh J, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729.
28. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas. Clin Cancer Res. 2008;14:7068-7073.
29. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008;26(May 20 suppl):abstr 2010b.
30. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413-2419.
31. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 2001;61(1):39-44.
32. Lai A, Filka E, McGibbon B, Nghiemphu PL, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372-1380.
33. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients. Cancer Cell. 2007;11(1):83-95.
34. R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-248.
35. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer. 2004;4 Suppl 2:S81-85.
36. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 2002;99(17):11393-11398.
37. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67(5):1526-1537.
38. De Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol. 2008;26(May 20 suppl): abstr 2020.
39. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery. 2004;55(2):426-432; discussion 432.
40. Yung WKA, Friedman H, Conrad C, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. Proceedings of the American Society of Clinical Oncology Meeting. Chicago, USA. 2003. Abstract 395.
41. Conrad C, Friedman H, Reardon D. A Phase I/II trial of single-agent PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1512.
42. Reardon D, Friedman H, Yung WKA, et al. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1513.
43. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51(8):2164-2172.
44. Pelloski CE, Zhang L, Lin E, et al. EGFRvIII status defi nes distinct subtypes of glioblastoma: an analysis of 649 cases. Proceedings of the Eleventh Annual Meeting of the Society for Neuro-Oncology. Orlando, USA. 2006. Abstract PA-26.
45. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133-142.
46. Uhm JH, Ballman KV, Giannini C, et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1505.
47. Lieberman FS, Cloughesy T, Fine H, et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans USA. 2004. Abstract 1510.
48. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67-78.
49. Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma mutliforme: Interim results. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1558.
50. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1502.
51. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012-2024.
52. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880-887.
53. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of plateletderived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60(18):5143-5150.
54. Geng L, Shinohara ET, Kim D, et al. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys. 2006;64(1):263-271.
55. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12(16):4899-4907.
56. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol. 2005;16(10):1702-1708.
57. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23(36):9359-9368.
58. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007;83(1):53-60.
59. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (Berl). 2004;108:467-470.
60. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430.
61. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24(22):3651-3656.
62. Gilbert MR, Gaupp P, Liu V, et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. Proceedings of the American Society of Clinical Oncology Meeting. Atlanta, USA. 2006. Abstract 1556.
63. Sathornsumetee S, Hjelmeland AB, Keir ST, et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006;66(17):8722-8730.
64. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic signifi cance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926-1933.
65. Momota H, Nerio E, Holland EC. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 2005;65:7429-7435.
66. Lassman A, Holland E, DeAngelis L, Panageas K, Abrey L. Clinical and molecular-metabolic phase II trial of perifosine for recurrent/ progressive malignant glioma. Neuro Oncol. 2007;9(4):467-602, Abstract MA-15.
67. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-361.
68. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294-5304.
69. Sawyers CL. Will kinase inhibitors have a dark side? N Engl J Med. 2006;355:313-315.
70. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006;9:341-349.
71. Hui AM, Zhang W, Chen W, et al. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004;64(24):9115-9123.
72. Brandes AA, Ermani M, Turazzi S, et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol. 1997;17(2):645-650.
73. Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL, Rostomily RC. Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neurooncol. 2004:70(1):91-95.
74. Robins HI, Won M, Seiferheld WF, et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. 2006;8(1):47-52.
75. Tang P, Roldan G, Brasher PM, et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro Oncol. 2006;78(3), 311-316.
76. Puchner MJ, Herrmann HD, Berger J, Cristante L. Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neurooncol. 2000;49(2):147-155.
77. Chang SM, Barker FG 2nd, Huhn SL, et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol. 1998;37(2):169-176.
78. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 1993;32(3):485-489; discussion 489-490.
79. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HC1), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005;65(16):7462-7469.
80. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas Proceedings of the American Society of Clinical Oncology Meeting. Orlando, USA. 2004. Abstract 1504.
81. Fine HA, Puduvalli VK, Chamberlain MC, et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent, intracranial glioblastoma multiforme (GBM): A phase III study. J Clin Oncol. 2008;26(May 20 suppl):abstr 2005.
82. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, et al. Alpha(v)beta3 and alpha(v)beta5integrin expression in glioma periphery. Nieurosurgery 2001;49(2):380-389(discussion 390).
83. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol. 1995;57(1-2):143-153.
84. Gladson CL. Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol. 1996;55(11):1143-1149.
85. Tucker GC: Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8(2):96-103.
86. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651-1657.
87. Reardon DA, Fink K, Nabors LB, Cloughesy T, Plotkin S, Schiff D, et al. Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. In 43rd Annual Meeting of American Society of Clinical Oncology. Edited by Grunberg SM. Chicago, IL: Lisa Greaves;2007:75s.
88. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007;25(Pt 1):No. 18S (June 20 Supplement).
89. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005;4(1):101-112.
90. Rich JN, Sathornsumetee S, Keir ST, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005;11(22):8145-8157.
91. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63(14):4009-4016.
92. Sathornsumetee S, Reardon DA, Quinn JA, et al. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Proceedings of the American Society of Clinical Oncology Meeting. Atlanta, USA. 2006. Abstract 1560.
93. Prados M, Yung W, Wen P, et al. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proceedings of the American Society of Clinical Oncology Meeting. New Orleans, USA. 2004. Abstract 1504.
94. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65(4):1192-1199.
95. Delmas C, Heliez C, Cohen-Jonathan E, et al. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer. 2002;100(1):43-48.
96. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24);7291-7297.
97. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys, 1992;24(1):55-57.
98. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology, 1980;30(9):907-911.
99. Brem H, Tamargo RJ, Olivi A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg. 1994;80(2);283-290.
100. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and effi cacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345(8956);1008-1012.
101. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
102. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60(3):853-860.
103. Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36(2):275-282; discussion 282-274.
104. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51(2):343-355; discussion 355-347.
105. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1005-1011.
106. Gabayan AJ, Green SB, Sanan A, et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery. 2006;58(4):701-709; discussion 701-709.
107. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18(22):3862-3872.
108. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20(5):1389-1397.
109. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24(1):115-122.
110. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 2001;46(1-3):149-168.
111. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076-2080.
112. Prados M, Kunwar S, Lang FF, et al. Final results of phase I/II studies of IL 13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. Proceedings of the American Society of Clinical Oncology Meeting. Orlando, USA. 2005. Abstract 1506.
113. Kunwar S, Westphal M, Medhorn M, et al. Results from PRECISE: a randomized phase 3 study in patients with first recurrent glioblastoma multiformed (GBM) comparing cintredekin besudotox (CB) administered via convection-enhanced delivery (CED) with Gliadel wafers (GW). Neuro Oncol. 2007;9(4):467-602 Abstract MA-61.